Teva Raises Guidance Amid Generics Growth
Firm Is Actively Examining BD Opportunities; Also Provides Update On Israel Conflict
Teva management sounded an optimistic note as the firm delivered its third-quarter results for 2023, adding a further $100m to the company’s full-year sales forecast and providing updates on a number of key aspects of the business.
